Core Viewpoint - Calidi Biotherapeutics, Inc. has successfully priced a public offering to raise $6 million, indicating strong interest from both existing and new investors despite challenging market conditions [1][2]. Group 1: Offering Details - The offering consists of 1,472,764 common stock units priced at $2.00 each, and 1,528,000 pre-funded warrant units priced at $1.999 each [2]. - Each common stock unit includes one share of common stock and one Series I warrant, while each pre-funded unit includes one pre-funded warrant and one Series I warrant [2]. - The Series I warrants have an exercise price of $2.00 per share and are exercisable upon issuance, expiring five years from issuance [2]. Group 2: Underwriting and Closing - Ladenburg Thalmann & Co. Inc. is the sole book-running manager for the offering, with Laidlaw & Company (U.K.) Ltd. acting as a co-manager [3]. - The underwriters have a 45-day option to purchase an additional 450,000 shares of common stock and/or warrants at the public offering price [3]. - The offering is expected to close on or about August 21, 2025, pending customary closing conditions [3]. Group 3: Company Overview - Calidi Biotherapeutics is a clinical-stage biotechnology company focused on developing targeted therapies for delivering genetic medicines to disease sites [6]. - The company's proprietary Redtail platform utilizes an engineered enveloped oncolytic virus for systemic delivery to metastatic sites, aiming to enhance the effectiveness of virotherapy [6]. - The lead candidate from the Redtail platform is currently in IND-enabling studies, targeting non-small cell lung cancer, ovarian cancer, and other high unmet medical need tumor types [7].